Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA

HANGZHOU, China and SHAOXING, China, Feb. 17, 2020 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code: 1672) announces today the application for in-house developed Category 1 Drug ASC41 for clinical trials of NASH indication has been accepted by China's National Medical Products...

from PR Newswire: https://ift.tt/2SBSe1Z